Merck's Sugammadex Sails Through FDA Panel But Faces Post-Approval Studies

Advisory committee suggests post-marketing epidemiological studies in higher risk patients to further assess risks of hypersensitivity, anaphylaxis and cardiac rhythm disorders with the neuromuscular blockade reversal agent.